Novartis says MS pill succeeds in two large studies
BioPharma Dive
Notably, Novartis revealed that remibrutinib wasn t associated with the kind of liver-related side effects other BTK inhibitors like it have encountered.
pharminent
September 1, 2026 (Last updated: September 2, 2026)
BioPharma Dive
Notably, Novartis revealed that remibrutinib wasn t associated with the kind of liver-related side effects other BTK inhibitors like it have encountered.